复发或难治性多发性骨髓瘤免疫治疗新进展

Recent advances in immunotherapy for relapsed or refractory multiple myeloma

免疫治疗策略在多发性骨髓瘤(MM)的治疗方面已显现出益处,但仍有一定比例的患者进展为复发或难治性MM。当前最新免疫治疗策略除了包括针对肿瘤细胞表面抗原的单克隆抗体外,双特异性抗体、免疫检查点抑制剂、嵌合抗原受体T细胞免疫、布鲁顿酪氨酸激酶抑制剂等为复发或难治性MM的免疫治疗提供了更多可能。

Immunotherapy strategies have shown benefits in the treatment of multiple myeloma(MM),however a certain percentage of patients progress to relapsed or refractory MM.In addition to monoclonal antibodies against antigens on tumor cells,the latest immunotherapy strategies include bispecific antibodies,immune checkpoint inhibitors,chimeric antigen receptor modified T cell and Bruton tyrosine kinase inhibitors,which provide more possibilities for immunotherapy of relapsed or refractory MM.